製品の概要

  • 製品名Anti-C3 antibody [8G4]
    C3 一次抗体 製品一覧
  • 製品の詳細
    Mouse monoclonal [8G4] to C3
  • 特異性Ab17455 is specific for an allotypic marker on human C3 (Leu instead of Pro in codon 314 of exon 9), which occurs regularly in the beta-chain of C3F and occasionally in the beta-chain of C3S. F and S mean fast and slow, respectively, on agarose gel electrophoresis. Ab17455 reacts with the 75-kDa beta-chain band on SDS-PAGE immunoblotting of reduced C3, and reacts with 20-kDa and 17-kDa beta-chain fragments produced by cyanogen bromide cleavage.
  • アプリケーション適用あり: ELISA, WBmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Full length native C3 protein isolated from human plasma.

  • エピトープThe exact epitope is not known, but the antibody is specific for the allotypic human C3 where Leu is found instead of Pro in codon 314 of exon 9.

製品の特性

  • 製品の状態Liquid
  • 保存方法Shipped at 4°C. Store at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • バッファーPreservative: None
    Constituents: 0.5M Sodium chloride, 0.01M PBS, pH 7.4
  • Concentration information loading...
  • 精製度Protein A purified
  • ポリ/モノモノクローナル
  • クローン名8G4
  • ミエローマx63-Ag8.653
  • アイソタイプIgG2a
  • 軽鎖の種類kappa
  • 研究分野

アプリケーション

Our Abpromise guarantee covers the use of ab17455 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ELISA 1/15000. Strong reaction is seen in ELISA with C3 coated directly onto the microtiter well.
WB Use at an assay dependent dilution. Detects a band of approximately 75 kDa (predicted molecular weight: 187 kDa). In Western blotting after SDS-PAGE, ab17455 detects the above-mentioned allotypic marker on the beta-chain of C3, closely related but not completely specific to the fast-moving form of C3, C3F.

ターゲット情報

  • 機能C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
    Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
  • 組織特異性Plasma.
  • 関連疾患Defects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:120700]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
    Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
    Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
  • 配列類似性Contains 1 anaphylatoxin-like domain.
    Contains 1 NTR domain.
  • 翻訳後修飾C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
    Phosphorylation sites are present in the extracelllular medium.
  • 細胞内局在Secreted.
  • Information by UniProt
  • 参照データベース
  • 別名
    • Acylation stimulating protein cleavage product antibody
    • AHUS5 antibody
    • ARMD9 antibody
    • ASP antibody
    • C3 and PZP like alpha 2 macroglobulin domain containing protein 1 antibody
    • C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1 antibody
    • C3 antibody
    • CO3_HUMAN antibody
    • Complement C3 antibody
    • Complement C3c alpha'' chain fragment 2 antibody
    • Complement component 3 antibody
    • Complement factor 3 antibody
    • CPAMD1 antibody
    • HEL S 62p antibody
    see all

Anti-C3 antibody [8G4] (ab17455) 使用論文

This product has been referenced in:
  • Behrendt N  et al. Localization and functional significance of a polymorphic determinant in the third component of human complement. Mol Immunol 24:1097-103 (1987). Read more (PubMed: 2446123) »

See 1 Publication for this product

Product Wall

Thank you for contacting us. Because we carry over 90,000 products, it isn't feasible for us to keep small sample sizes of our products.

We are happy to reassure our customers that all of our products are covered by our Abpromise, which guaran...

Read More

Thank you for your enquiry. This antibody reacts with the C3F, which is a beta-chain genetic variant. I have updated the datasheet with the information I have received. Ab17455 is specific for an allotypic marker on human C3 (Leu instead of Pro...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"